61,252 Shares in Novo Nordisk A/S (NYSE:NVO) Bought by Caprock Group LLC

Caprock Group LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 61,252 shares of the company’s stock, valued at approximately $7,293,000.

Other institutional investors have also recently made changes to their positions in the company. Advisor OS LLC boosted its holdings in Novo Nordisk A/S by 0.6% in the second quarter. Advisor OS LLC now owns 13,972 shares of the company’s stock valued at $1,994,000 after acquiring an additional 82 shares during the last quarter. Cascade Financial Partners LLC boosted its stake in shares of Novo Nordisk A/S by 2.3% in the 2nd quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company’s stock valued at $543,000 after purchasing an additional 84 shares during the last quarter. Novare Capital Management LLC increased its position in shares of Novo Nordisk A/S by 3.2% during the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock worth $325,000 after buying an additional 85 shares during the period. AA Financial Advisors LLC raised its stake in Novo Nordisk A/S by 3.2% during the second quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock worth $400,000 after buying an additional 86 shares during the last quarter. Finally, Steel Grove Capital Advisors LLC lifted its holdings in Novo Nordisk A/S by 2.3% in the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after buying an additional 86 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on NVO shares. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $99.82 on Tuesday. The stock’s 50 day moving average is $117.94 and its 200-day moving average is $129.42. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $447.95 billion, a price-to-earnings ratio of 32.30, a PEG ratio of 1.31 and a beta of 0.42.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.